Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne Floquet

Showing results (21-30 of 96) with videos related to

Pageof 10
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 2, 2009
Prognostic factors in early-stage leiomyosarcoma of the uterusManuela Pelmus, Frédérique Penault-Llorca, Louis Guillou, et al.
Cancers|May 14, 2022
Biomarkers Associated with Lymph Nodal Metastasis in Endometrioid Endometrial CarcinomaMathilde Mairé, Aurélien Bourdon, Isabelle Soubeyran, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 20, 2013
YWHAE rearrangement identified by FISH and RT-PCR in endometrial stromal sarcomas: genetic and pathological correlationsSabrina Croce, Isabelle Hostein, Agnes Ribeiro, et al.
Bulletin Du Cancer|December 27, 2021
Prise en charge médicale de la récidive du cancer épithélial de l'ovaire: Medical management of recurrent epithelial ovarian cancerPatricia Pautier, Thibault de la Motte-Rouge, Fabrice Lécuru, et al.
The American Journal of Surgical Pathology|July 3, 2015
SMARCA4 (BRG1) loss of expression is a useful marker for the diagnosis of ovarian small cell carcinoma of the hypercalcemic type (ovarian rhabdoid tumor): a comprehensive analysis of 116 rare gynecologic tumors, 9 soft tissue tumors, and 9 melanomasMarie Karanian-Philippe, Valérie Velasco, Michel Longy, et al.
Drugs - Real World Outcomes|January 11, 2023
Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data StudyCharlotte Bellier, Laurence Gladieff, Fanny Le Du, et al.
Nature Communications|June 4, 2024
Author Correction: Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO groupGilles Freyer, Anne Floquet, Olivier Tredan, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 18, 2014
Gynecologic Cancer InterGroup (GCIG) consensus review for endometrial stromal sarcomaFrédéric Amant, Anne Floquet, Michael Friedlander, et al.
Nature Communications|March 5, 2024
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO groupGilles Freyer, Anne Floquet, Olivier Tredan, et al.
Journal of Hematology & Oncology|February 10, 2017
Clinical impact of extensive molecular profiling in advanced cancer patientsSophie Cousin, Thomas Grellety, Maud Toulmonde, et al.
Pageof 10

Showing results (21-30 of 96) with videos related to

Sort By:
Pageof 10
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 2, 2009
Prognostic factors in early-stage leiomyosarcoma of the uterusManuela Pelmus, Frédérique Penault-Llorca, Louis Guillou, et al.
Cancers|May 14, 2022
Biomarkers Associated with Lymph Nodal Metastasis in Endometrioid Endometrial CarcinomaMathilde Mairé, Aurélien Bourdon, Isabelle Soubeyran, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 20, 2013
YWHAE rearrangement identified by FISH and RT-PCR in endometrial stromal sarcomas: genetic and pathological correlationsSabrina Croce, Isabelle Hostein, Agnes Ribeiro, et al.
Bulletin Du Cancer|December 27, 2021
Prise en charge médicale de la récidive du cancer épithélial de l'ovaire: Medical management of recurrent epithelial ovarian cancerPatricia Pautier, Thibault de la Motte-Rouge, Fabrice Lécuru, et al.
The American Journal of Surgical Pathology|July 3, 2015
SMARCA4 (BRG1) loss of expression is a useful marker for the diagnosis of ovarian small cell carcinoma of the hypercalcemic type (ovarian rhabdoid tumor): a comprehensive analysis of 116 rare gynecologic tumors, 9 soft tissue tumors, and 9 melanomasMarie Karanian-Philippe, Valérie Velasco, Michel Longy, et al.
Drugs - Real World Outcomes|January 11, 2023
Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data StudyCharlotte Bellier, Laurence Gladieff, Fanny Le Du, et al.
Nature Communications|June 4, 2024
Author Correction: Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO groupGilles Freyer, Anne Floquet, Olivier Tredan, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 18, 2014
Gynecologic Cancer InterGroup (GCIG) consensus review for endometrial stromal sarcomaFrédéric Amant, Anne Floquet, Michael Friedlander, et al.
Nature Communications|March 5, 2024
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO groupGilles Freyer, Anne Floquet, Olivier Tredan, et al.
Journal of Hematology & Oncology|February 10, 2017
Clinical impact of extensive molecular profiling in advanced cancer patientsSophie Cousin, Thomas Grellety, Maud Toulmonde, et al.
Pageof 10